Rituximab plus lenalidomide in advanced untreated follicular lymphoma

Researchers evaluated an alternative intervention for patients with advanced-stage, previously untreated follicular lymphoma. The combination of rituximab and chemotherapy is effective but with high levels of relapse, but investigators hypothesized that pairing rituximab with lenalidomide instead might generate better outcomes.

Researchers evaluated an alternative intervention for patients with advanced-stage, previously untreated follicular lymphoma. The combination of rituximab and chemotherapy is effective but with high levels of relapse, but investigators hypothesized that pairing rituximab with lenalidomide instead might generate better outcomes. They recruited 1,030 international patients matching the disease profile for the Phase III RELEVANCE trial. Patients randomized to either treatment had similar rates of confirmed or unconfirmed complete response at 120 weeks and similar rates of progression-free survival at 3 years. Where they differed, however, was in their safety profiles. More patients in the chemotherapy group suffered grade 3 or 4 neutropenia and febrile neutropenia of any grade, while more participants in the lenalidomide group experienced grade 3 or 4 cutaneous reactions.